CATALYSIS Advises Orphan Oncology Company ERYTECH Pharma SA on €5.0 Million Convertible Note

CATALYSIS CAPITAL PARTNERS is pleased to announce that it acted as the exclusive financial advisor to ERYTECH Pharma SA in securing  €5.0 million from Recordati in the form of a convertible note.  The transaction was concurrent with ERYTECH Pharma signing a licensing and distribution agreement with Orphan Europe for GRASPA® in Europe.  Orphan Europe is part of the Recordati Group. Read more